We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Chemosensor Detects Cancer Biomarker Neopterin

By LabMedica International staff writers
Posted on 02 Jun 2016
A procedure has been established of molecular imprinting; a synthetic polymer receptor for the neopterin cancer biomarker was devised and used as a recognition unit of a potentiometric chemosensor.

Cancer is no longer a death sentence for the patient, but the best chances of recovery are when the correct treatment is undertaken at an early stage of the disease. More...
This is where the trouble starts, because many tumors develop over a long period without any symptoms.

Scientists at the Institute of Physical Chemistry of the Polish Academy of Sciences (Warsaw, Poland) devised and fabricated a chemosensor system that will bring us a step closer to the sort of personalized medical diagnosis and cancer prophylaxis in the near future. The most important element of the devised chemosensor is a thin film of the polymer that detects molecules of neopterin. Neopterin, in chemical terminology known as 2-amino-6-(1,2,3-trihydroxypropyl)-1H-pteridin-4-one), is an aromatic compound present in human body fluids, such as serum, urine, and cerebrospinal fluid.

The concentration of this neopterin biomarker rises significantly particularly in the case of certain neoplastic diseases, e.g., malignant lymphoma, although elevated levels of neopterin are also seen in some viral and bacterial infections, as well as in diseases of parasitic etiology. In turn, in transplant patients, increased levels of neopterin signal probable rejection. The device has a recognizing polymer film with molecular cavities from neopterin has been produced on the surface of an electrode. Electrochemical experiments involving the potentiodynamic, cyclic voltammetry(CV), and open circuit potential (OCP) measurements were performed with an SP300 electrochemistry system (BioLogic Science Instruments, Claix, France).

After immersion in artificial blood serum spiked with neopterin, the film on the electrode captured molecules of the latter, thus leading to a decrease in electrical potential in the connected measuring system. The tests showed that the molecular cavities of the polymer were almost entirely filled with molecules of neopterin despite the presence of molecules of similar structure and properties. This result means that the probability of false positive detection (detecting the presence of neopterin in body fluids not containing it) is negligibly small. The new chemical sensor therefore mainly reacts to what it should react to - and nothing else.

Wlodzimierz Kutner, PhD, DSc, a professor of Chemistry and lead author of the study said. “At present, our chemosensor is a piece of laboratory equipment. However, the production of its key element, that is, the recognizing polymer film, does not pose major problems, and the electronics responsible for electrical measurements can easily be miniaturized. There is nothing standing in the way of building simple and reliable diagnostic equipment, based on our development, in just a few years' time, which would be affordable for medical institutions and doctors' surgeries.” The study was published on March 15, 2016, in the journal Biosensors and Bioelectronics.

Related Links:
Institute of Physical Chemistry of the Polish Academy of Sciences
BioLogic Science Instruments

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Autoimmune Hepatitis Test
LKM-1-Ab ELISA
New
Anti-Thyroid Peroxidase Assay
LIAISON Anti-TPO
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: New research brings hope for improved early detection of pancreatic cancer (Photo courtesy of Adobe Stock)

New Biomarker Panel to Enable Early Detection of Pancreatic Cancer

Pancreatic cancer (PC) has one of the worst prognoses globally, with only 13% of diagnosed patients surviving for five years or more. In Ireland, there are about 900 cases of pancreatic cancer annually,... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.